Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2004.041087v1, 2005; 10.1373/clinchem.2004.041087
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplements
Right arrow All Versions of this Article:
clinchem.2004.041087v1
51/4/695    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Le, L.
Right arrow Articles by Sadar, M. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Le, L.
Right arrow Articles by Sadar, M. D.

Received on August 2, 2004
Accepted on January 12, 2005

Proteomics and Protein Markers

Identification of Serum Amyloid A as a Biomarker to Distinguish Prostate Cancer Patients with Bone Lesions

Lyly Le 1, Kim Chi 1, Scott Tyldesley 1, Stephane Flibotte 1, Deborah L. Diamond 2, Michael A. Kuzyk 1, Marianne D. Sadar 1*

1 British Columbia Cancer Agency, Vancouver, British Columbia, Canada
2 Ciphergen Biosystems, Inc., Fremont, CA

* To whom correspondence should be addressed. E-mail: msadar{at}bccancer.bc.ca.

Background: Prostate cancer has a propensity to metastasize to the bone. Currently, there are no curative treatments for this stage of the disease. Sensitive biomarkers that can be monitored in the blood to indicate the presence or development of bone metastases and/or response to therapies are lacking. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) is an affinity-based approach that allows sensitive and high-throughput protein profiling and screening of biological samples.

Methods: We used SELDI-TOF MS for protein profiling of sera from prostate cancer patients (n = 38) with and without bone metastases in our effort to identify individual or multiple serum markers that may be of added benefit to those in current use. Serum was applied to ProteinChip® surfaces (H4 and IMAC) to quickly screen samples and detect peaks predominating in the samples obtained from patients with bone metastases. Unique proteins in the bone metastasis cohort observed by SELDI-TOF MS were identified by two-dimensional gel electrophoresis, in-gel trypsin digestion, and tandem MS. The identities of the proteins were confirmed by ELISA and immunodepletion assays.

Results: The cluster of unique proteins in the sera of patients with bone metastases was identified as isoforms of serum amyloid A. Machine-learning algorithms were also used to identify patients with bone metastases with a sensitivity and specificity of 89.5%.

Conclusions: SELDI-TOF MS protein profiling in combination with other proteomic approaches may provide diagnostic tools with potential clinical applications and serve as tools to aid in the discovery of biomarkers associated with various diseases.




The following articles in journals at HighWire Press have cited this article:


Home page
J. Lipid Res.Home page
S. I. van Leuven, R. Hezemans, J. H. Levels, S. Snoek, P. C. Stokkers, G. K. Hovingh, J. J. P. Kastelein, E. S. Stroes, E. de Groot, and D. W. Hommes
Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease
J. Lipid Res., December 1, 2007; 48(12): 2640 - 2646.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
D. Nedelkov, U. A. Kiernan, E. E. Niederkofler, K. A. Tubbs, and R. W. Nelson
Population Proteomics: The Concept, Attributes, and Potential for Cancer Biomarker Research
Mol. Cell. Proteomics, October 1, 2006; 5(10): 1811 - 1818.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
G. L. Hortin
The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome
Clin. Chem., July 1, 2006; 52(7): 1223 - 1237.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the American Association for Clinical Chemistry.